Literature DB >> 20009140

De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis.

Carmen Landaverde1, Vivian Ng, Alisa Sato, James Tabibian, Francisco Durazo, Ronald Busuttil.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, progressive, inflammatory and obstructive disease of the intra- and extra-hepatic bile ducts of unknown etiology. Currently, orthotopic liver transplantation (OLT) is the only definitive treatment for PSC-related end-stage liver disease. However, PSC has been known to recur in the grafted liver. Roux-en-Y hepaticojejunostomy is more commonly performed than choledochocholedochostomy for PSC, although choledochocholedochostomy has been found to be safe and efficacious for PSC if the distal common bile duct is uninvolved at the time of OLT. Our case is unique in that it describes a patient who developed de-novo cholangiocarcinoma in the remnant portion of the native common bile duct six years after OLT with choledochocholedochostomy for PSC-associated end-stage liver disease without having PSC recurrence. In conclusion, our case report indicates that choledochocholedochostomy may not be desirable in PSC due to an increased risk of developing cholangiocarcinoma in the native common bile duct. This risk exists as well with a Roux-en-Y hepaticojejunostomy in the remaining intra-duodenal and intra-pancreatic biliary epithelium, although in theory to a lesser extent. Therefore, the risk of developing cholangiocarcinoma in the recipient common bile duct can only be completely eliminated by performing a Whipple procedure at the time of OLT.

Entities:  

Mesh:

Year:  2009        PMID: 20009140

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  5 in total

1.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

Review 2.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

3.  Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-07

4.  Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis.

Authors:  James H Tabibian; Christy E Trussoni; Steven P O'Hara; Patrick L Splinter; Julie K Heimbach; Nicholas F LaRusso
Journal:  Lab Invest       Date:  2014-07-21       Impact factor: 5.662

Review 5.  Role of the microbiota and antibiotics in primary sclerosing cholangitis.

Authors:  James H Tabibian; Jayant A Talwalkar; Keith D Lindor
Journal:  Biomed Res Int       Date:  2013-10-22       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.